Skip to main content

Advertisement

Table 3 Quality of life of mRCC patients at baseline and 3 months after treatment with sorafenib and sunitinib

From: Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma

SF-36 dimension At baseline (score) P value Three months after treatment (score) P value
Sorafenib group (n = 110) Sunitinib group (n = 74) Sorafenib group (n = 110) Sunitinib group (n = 74)
PF 68.9 ± 20.9 67.8 ± 19.5 0.548 66.7 ± 24.0 67.1 ± 20.3 0.914
RP 38.2 ± 36.6 45.6 ± 34.2 0.167 36.5 ± 37.5 42.7 ± 40.1 0.527
BP 77.2 ± 16.0 78.7 ± 20.2 0.587 76.2 ± 16.7 77.4 ± 19.7 0.646
GH 56.0 ± 16.3 54.4 ± 20.2 0.531 54.7 ± 15.1 50.8 ± 19.4 0.152
VT 70.1 ± 20.6 71.0 ± 16.1 0.759 68.7 ± 21.7 69.3 ± 15.8 0.858
SF 80.5 ± 18.6 82.1 ± 15.7 0.531 78.5 ± 19.2 80.2 ± 17.3 0.571
RE 59.1 ± 6.3 63.1 ± 33.4 0.452 55.5 ± 39.7 58.6 ± 37.4 0.594
MH 71.1 ± 12.5 75.2 ± 9.8 0.050 69.7 ± 15.7 75.8 ± 14.4 0.055
  1. PF physical functioning, RP role-physical, BP bodily pain, GH general health, VT vitality, SF social functioning, RE role-emotional, MH mental health